Indena: New Brazil Office to Extend Reach in Thriving Latin American Market
29 April 2014 --- Indena has opened an affiliate in Sao Paulo, Brazil to further support the distributor’s presence in the thriving Latin American markets. Indena Brasil Ltda will play a key role to enhance a direct presence in Brazil in the pharmaceutical, nutraceutical and cosmetic fields.
“By opening a new affiliate in São Paulo we are getting closer to our existing customers, being able at the same time to further improve our growing client base in the Region,” commented Daniele Giavini, Managing Director of Indena. “We will be able to better meet their needs, providing the high level quality that Indena has been supplying for more than ninety years in the market of natural ingredients”.
“In addition”, added Alessio Tagliaferri, General Manager of Indena Brasil, “establishing a local entity means also enhancing our distribution capabilities, reducing our time to market and increasing our services”.
The Latin American market is showing ‘remarkable signs of growth’, according to Indena, in the company’s key areas of pharmaceutical, nutraceutical and cosmetic markets.
Indena is the leading company dedicated to the identification, development and production of high quality active principles derived from plants, for use in the pharmaceutical, health food and personal care industries.
Backed up by 90 years of botanical experience, the company has more than 120 primary patents and has published more than 700 scientific studies and co-operates with the world’s most prestigious universities and private research institutions.
Indena employs about 800 staff, investing around 10% of its annual turnover in research, making this activity the key to its success. Headquartered in Milan, Indena has five production sites and five international branches throughout the world and manages sales in more than 70 countries. The Company's experts communicate and interact constantly with the major international regulatory authorities such as WHO, EMA, and ESCOP, and cooperate on the update of all the main pharmacopoeias.
